Saving changes...

Done

Error

2018 ACCP Journal of Clinical Pharmacology Journal CE October | Cystatin C Is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies

2018 ACCP Journal of Clinical Pharmacology Journal CE October | Cystatin C Is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies

2018 ACCP Journal of Clinical Pharmacology Journal CE October | Cystatin C Is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies

Sumit Kar, BS, Sabina Paglialunga, PhD, and Rafiqul Islam, MS
Sumit Kar, BS, Sabina Paglialunga, PhD, and Rafiqul Islam, MS
on behalf of American College of Clinical Pharmacology

$10.00 $ 10.00 $ 10.00

$10.00 $ 10.00 $ 10.00

$ 10.00 $ 10.00 $ 10.00
$ 10.00 $ 10.00 $ 10.00
Normal Price: $10.00 $10.00

Review:

Launch date: 11 Oct 2018
Expiry Date: 31 Dec 2020

Last updated: 18 Dec 2018

Reference: 192796

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Learners that complete this course will be able to describe explain the value of cystatin C as a reliable marker for eGFR determination in drug development.

Objectives

Explain the physiology of cystatin C
After completing this activity, the learner will be able to explain the physiology of cystatin C.
List the advantages of using cystatin C over Creatinine for staging Chronic Kidney Disease
After completing this activity, the learner will be able to list the advantages of using cystatin C over Creatinine for staging Chronic Kidney Disease.
Identify studies showing better predictive value of cystatin C for adverse effects of eGFR
After completing this activity, the learner will be able to identify studies showing better predictive value of cystatin C for adverse effects of eGFR.
List limitations of using cystatin C as a GFR biomarker
After completing this activity, the learner will be able to list limitations of using cystatin C as a GFR biomarker.
Sumit Kar, BS, Sabina Paglialunga, PhD, and Rafiqul Islam, MS

Author Information Play Video Bio

Sumit Kar, BS, Sabina Paglialunga, PhD, and Rafiqul Islam, MS
on behalf of American College of Clinical Pharmacology

In the 1960s, a group of eminent physicians formulated the concept of an organization dedicated to a new branch of pharmacology that dealt with the effectiveness and safety of drugs in man. As a result of their efforts, the American College of Clinical Pharmacology (ACCP) was founded on September 11, 1969. Today, ACCP consists of a full spectrum of clinical pharmacology professionals from academia, industry, government and clinical settings who span the scope from research and drug development to patient-related care and who remain dedicated to advancing clinical pharmacology with the ultimate goal of enhancing patient care.

As an organization whose primary role is education, ACCP does not concentrate on any one aspect of the discipline. Rather, it seeks to address the educational needs of its diverse membership and all healthcare professionals, covering a range of topics that span the entire area of the interaction between drugs and humans. These areas include, but are not limited to, pharmaceutical chemistry, biochemistry, drug metabolism, pharmacokinetics, pharmacodynamics, pharmacometrics, pharmacogenomics clinical pharmacology practice in the outpatient and inpatient settings, human toxicology, drug interactions and clinical drug trials. The diversity of ACCP is expressed not only in the composition of its membership, but also in its leadership. Maintaining a balance of elected Regents and Officers from all pertinent professional backgrounds ensures that ACCP remains attuned to the needs of all professionals engaged in the practice of or with a strong interest in clinical pharmacology, from the research laboratory (academic and industrial) to the classroom, and from clinical trials to improved patient care.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.00 Credits
  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.00 Hours -
    Exam Pass Rate: 75

Faculty and Disclosures

Joseph Bertino,  PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc

Joseph Bertino, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc

Nothing to disclose.
Otito Frances Iwuchukwu, RPh, PhD, Assistant Professor, Fairleigh Dickinson Univ School of Pharmacy, Pharmaceutical Sciences

Otito Frances Iwuchukwu, RPh, PhD, Assistant Professor, Fairleigh Dickinson Univ School of Pharmacy, Pharmaceutical Sciences

Nothing to disclose.
David F. Kisor, BS, PharmD, FCP, Director of Pharmacogenomics Education, Manchester University, Dept of Pharmaceutical Sciences & Pharmacogenomics

David F. Kisor, BS, PharmD, FCP, Director of Pharmacogenomics Education, Manchester University, Dept of Pharmaceutical Sciences & Pharmacogenomics

Nothing to disclose.

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error